1. Di Bisceglie AM. 1998; Hepatitis C. Lancet 351: 351-355.
2. Butler T., Kariminia A., Levy M., Kaldor J. 2004; Prisoners are at risk for hepatitis C transmission. Eur J Epidemiol 19: 1119-1122.
3. Feinman S.V., Berris B., Bojarski S. 1988; Posttransfusion hepatitis in Toronto, Canada. Gastroenterology 95: 464-469.
4. Simmonds P. 1995; Variability of hepatitis C virus. Hepatology 21:
570-583.
5. Lemon S. and Brown E. 1994; Hepatitis C virus and chronic liver disease. In: Swartzand M.N. and Remington, J.S. (eds.), “Current clinical Topics in infection disease”. New York, Vol. 14, pp. 121-141.
6. Mondelli MU., Manns M. and Ferrari C. 1988; Does the immune response play a role in the pathogenesis of chronic liver disease? Arch Pathol Lab Med 112: 489-497.
7. Szabo G. and Dolganiuc A. 2006; HCV immunopathogenesis:
virus-induced strategies against host immunity. Clin Liver Dis 10:
753-771.
8. Choi J., Xu Z. and Ou J.H. 2003; Triple decoding of hepatitis C virus RNA by programmed translational frameshifting. Mol Cell Biol 23:
1489-1497.
9. Choi J., Lee K.J., Zheng Y., Yamaga AK., Lai MM. and Ou J.H. 2004;
Reactive oxygen species suppress hepatitis C virus RNA replication in human hepatoma cells. Hepatology 39: 81-89.
10. Walewski JL., Keller TR., Stump DD. and Branch AD. 2001; Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 7: 710-721.
11. Xu Z., Choi J., Yen T.S., Lu W., Strohecker A., Govindarajan S., Chien D., Selby MJ. and Ou J. 2001; Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. Embo J 20: 3840-3848.
12. Varaklioti A., Vassilaki N., Georgopoulou U. and Mavromara P. 2002;
Alternate translation occurs within the core coding region of the hepatitis C viral genome. J Biol Chem 277: 17713-17721.
13. Alter HJ., Sanchez-Pescador R., Urdea MS., Wilber JC., Lagier RJ., Di Bisceglie AM., Shih J.W., Neuwald PD. 1995; Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepatol 2: 121-132.
14. Sydiskis RJ., Owen DG., Lohr JL., Rosle, KH. and Blomster RN. 1991;
Inactivation of enveloped viruses by anthraquinones extracted from plants. Antimicrob Agents Chemother 35: 2463-2466.
15. Yao E. and Tavis JE. 2005; A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virol J 2: 88.
16. Nishiguchi S., Ueda T., Itoh T., Enomoto M., Tanaka M. and Tatsumi N 2001; Method to detect substitutions in the interferon-sensitivity- determining region of hepatitis C virus 1b for prediction of response to interferon therapy. Hepatology . 33: 241-7.
17. Takada N., Takase S., Enomoto N., Takada A. and Date T. 1992; Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatol 14: 35-40.
18. Taylor DR., Shi S.T. and Lai M.M. 2000; Hepatitis C virus and interferon resistance. Microbes Infect 2: 1743-1756.
19. Verbeeck J., Maes P., Lemey P., Pybus OG., Wollants E., Song E., Nevens F., Fevery J., Delport W., Van der Merwe S. and , Van Ranst M.
2006; Investigating the origin and spread of hepatitis C virus genotype 5a. J Virol 80: 4220-4226.
20. Podevin P., Guechot J., Serfaty L., Morand-Joubert L., Veyrunes C. and Bonnefis MT. 1997; Evidence for a deficiency of interferon response in mononuclear cells from hepatitis C viremic patients. J Hepatol 27:
265-71.
21. Lohmann V., Korner F., Koch J., Herian U., Theilmann L. and Bartenschlager R. 1999; Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113.
22. Martin J., Quiroga JA, Navas S., Pardo M. and Carreno, V 1999;
Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells.
Cytokine 11: 267-273.
23. Wurmbach E., Chen Y.B., Khitrov G., Zhang W., Roayaie S., Schwartz M., Fiel I., Thung S., Mazzaferro V., Bruix J., Bottinger E., Friedman S., Waxman S. and Llovet J.M. 2007; Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma Hepatology volum 45, Issue 4:938-947
24. Donadel E., Pontisso P., Ruvoletto MG., Gerotto M. De Salvo G., Chemello L., Casarin C. and Alberti A. 1998; Characteristics of hepatitis C virus before and after interferon treatment in patients with ongoing viraemia but sustained biochemical response. J Med Virol 54: 7-11.
25. Hoofnagle JH., di Bisceglie AM. 1997; The treatment of chronic viral hepatitis. N Engl J Med 336: 347-56.
26. Neumann AU., Lam NP., Dahari H., Gretch DR., Wiley TE., Layden TJ.
and Perelson AS. 1998; Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282: 103-107.
27. Shindo M., Di Bisceglie AM., Cheung L., Shih JW., Cristiano K., Feinstone SM. and Hoofnagle JH 1991; Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 115: 700-704
28. Glue P., Rouzier-Panis R., Raffanel C., Sabo R., Gupta SK, Salfi M., Jacobs S. and Clement RP. 2000; A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 32: 647-653
29. Shields PL., Mutimer DJ., Muir D., Skidmore S., Britnell T., Roberts A.
and Wilde JT. 2000; Combined alpha interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders.
Br J Haematol 108: 254-258
30. Wohnsland A., Hofmann WP. and Sarrazin C. 2007; Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 20: 23-38.
31. 李乾溝 2001; 實用中醫消化病學。 北京人民衛生出版社 673-677.
32. 唐智敏陸定波 朱清靜 1999; 中醫研究丙型肝炎的進展。中國中醫 基礎醫學雜誌 5(4)︰56.
33. 任進余、 雪成多、 王靈台 1999; 中醫對丙型肝炎的認識及治療現 狀。 中西醫結合肝病雜誌 9(1)︰59.
34. 王靈台：2001; 清肝沖劑、補腎沖劑治療丙型肝炎的臨床療效觀察。
海峽兩岸中西醫治療肝病學術研究論文集 1-7.
35. 岡部和彥 1994; 小柴胡湯對慢性丙性肝炎的臨床效果。 診斷與治療 82(5)︰37.
36. 何妙嬋 鄭其進 1996; 赤白桃虎湯治療慢性丙型肝炎 27 例臨床療效 觀察。 新中醫 28 (9)︰47.
37. 金實 汪悅 1998; 慢性丙性肝炎中醫辯證分型和臨床檢驗指標關係 的探討。 中醫雜誌 39(4)︰233.
38. 吳聖明 1996;中醫治療慢性丙型肝炎 58 例。 陜西中醫 14(7)：316 39. 孫明輝 1996; 丙肝煎治療慢性丙型肝炎 48 例。 浙江中醫雜誌
1(3)︰47.
40. 馬素雲 裴志剛 1996; 中西醫結合治療慢性丙型肝炎 46 例。 中國 中西醫結合雜誌 16(9)︰558.
41. 李厚根 高鴻 蔡靜玲 1996; 清退方治療丙型肝炎 128 例。 中西醫結 合肝病雜誌 4(2)︰8.
42. 張穎 禇貴寶 2001; 中醫藥及中西醫結合治療慢性乙型肝炎的進 展。 河北中醫 23(7)：555.
43. 落合宏 1991; 國外醫學中醫中藥分冊 13(4)：43.
44. 溝口靖紘 1986; 和漢醫藥學會誌 (日文) 3(3)：184.
45. 志村圭志郎 1984; 漢方醫學 (日文) 8(4)：13.
46. 傅元謀 1988; 國外醫學 中醫中藥分冊 10(1)：4.
47. 梁嶸 1991; 國外醫學 中醫中藥分冊 13(5)：39.
48. Wang S.Y., Hsu M.L., Hsu H.C., Tzeng C.H., Lee S.S., Shiao M.S. and Ho C.K. 1997; The anti-tumor effect of Ganoderma lucidum is mediated by cytokine released from activated macrophages and T lymphocytes.
Int J Cancer 70: 699-705.
49. Zhu M., Chang Q., Wong .LK., Chong F.S. and Li R.C. 1999; Triterpene antioxidants from ganoderma lucidum. Phytother Res 13: 529-531.
50. Tsuboi H., Hossain K., Akhand AA, Takeda K., Du J., Rifa'i M., Dai Y., Hayakawa A., Suzuki H. and Nakashima I. 2004; Paeoniflorin induces apoptosis of lymphocytes through a redox-linked mechanism. J Cell Biochem 93: 162-172.
51. Komoda Y., Shimizu M., Sonoda Y. and Sato Y. 1989; Ganoderic acid and its derivatives as cholesterol synthesis inhibitors. Chem Pharm Bull (Tokyo) 37: 531-533.
52. Kim DH., Shim SB., Kim NJ. and Jang IS. 1999;
eta-glucuronidase-inhibitory activity and hepatoprotective effect of Ganoderma lucidum. Biol Pharm Bull 22: 162-164.
53. 譚樹輝 2005; 常用中草藥百科（一）。 西北出版社 pp.185.
54. 陳萬生 1993; 知 母抗炎作用初探。 藥學情報通訊 11(3):14.
55. 胡雅兒 1990; 甲亢小鼠腦 M 受體的變化及滋陰藥的調解作用。 上 海第二醫科大學學報10(3)：274.
56. 丁元生 1990; 知母皂苷元對甲高小鼠腦βAR 的下調作用。中藥藥 理與臨床 6(2)： 15.
57. 楊文乾 2002; 神奇草藥大圖鑑 3 。林鬱文化事業有限公司 pp.504.
58. 安‧麥金泰 1996; 香藥草。 綠生活國際股份有限公司 pp. 63.
59. 婁紅祥 1996; 金銀花水溶性化合物的分離與結構確定。 中草藥 27
（4）：195-196
60. 高淑娟 1992; 幾種清熱解毒中藥抗內毒素作用的比較實驗。 天津中
醫（2）：42.
61. 羅中華 1994; 三七等四種中藥對燙傷小鼠巨噬細胞功能的作用 中 華醫學雜誌 74（10）：634-635.
62. 王輝雲 1994; 計量分析甘草甜素和絞股藍總苷等對大鼠肝癌前病變 的影響 中山醫科大學學報 15（1）：37-38.
63. 陳金陵 1994; 絞股藍的藥理作用。中國醫院藥學雜誌 14（7）：320 64. 齊剛 1995; 絞股藍研究新發展。 中草藥 26（7）：377-378.
65. 楊鑒英 1989; 中藥抗乙型肝炎病毒的實驗研究。 中西醫結合雜誌 9(8)：494.
66. 王立明 1996; 黃芩有效成分對四氯化碳致損的原代培養大鼠肝細胞 的作用。 浙江醫科大學學報 25(6):241.
67. (日)小泉久仁彌 1995; 白芷、黃芩對大鼠肝藥物代謝酶的影響。 國 外醫學中醫中藥分冊 17(4)： 30.
68. (日)罔田和也 1996; 大黃、黃芩對 HepG2 細胞增殖的抑制作用。 國 外醫學中醫中藥分冊 18(1)：35.
69. Li Y.Q. and Wang S.F. 2006; Anti-hepatitis B activities of ganoderic acid from Ganoderma lucidum. Biotechnol Lett 28: 837-841.
70. Hwang, DR, Wu, YS, Chang, CW, Lien, TW, Chen, WC, Tan, UK, Hsu, JT and Hsieh, HP 2006; Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system. Bioorg Med Chem 14: 83-91.
71. Rino, Y, Tarao, K, Morinaga, S, Ohkawa, S, Miyakawa, K, Hirokawa, S, Masaki, T, Tarao, N, Yukawa, N, Saeki, H, Takanashi, Y and , Imada, T 2006; Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.
Anticancer Res 26: 2221-2226.
72. Huang S.P., Shieh G.J., Lu H.C., Lin J.G. and Chen J.C. 2003; Effect of Xaio Chai Hu Tang in Peripheral Blood Mononuclear cells of HCV patients in Taiwan. The National Union of Chinese Medical Associations, R.O.C. 2: 80-92.
73. Pawlotsky JM.., Bouvier-Alias M., Hezode C., Darthuy F., Remire J. and Dhumeaux D. 2000; Standardization of hepatitis C virus RNA quantification. Hepatology 32: 654-659.
74. Unutmaz D., Pileri P. and Abrignani S. 1994; Antigen-independent activation of naive and memory resting T cells by a cytokine combination. J Exp Med 180: 1159-64.
75. Hwang D.R., Tsai Y.C., Lee J.C., Huang K.K., Lin R.K., Ho C.H., Chiou J.M., Lin Y.T., Hsu J.T. and Yeh C.T. 2004; Inhibition of hepatitis C virus replication by arsenic trioxide. Antimicrob agents Chemother 48:2876-2882.
76. Keskinen P., Melen K. and Julkunen I. 2002; Expression of HCV structural proteins impairs IFN-mediated antiviral response.Virology 299:164.
77. Huang S.P., Shieh G.J., Lee L.L., Teng H.J., Kao S.T. and Lin J.G. 1997;
Inhibition effect of shengma-gegen-tang on measles virus in Vero cells and human peripheral blood mononuclear cells. Am J Chin Med 25:
89-96.
格式化: 置中, 左 0 字元, 第 一行: 0 字元, 右 0 字元, 格 線被設定時，自動調整右側 縮排, 間距 套用前: 0 pt, 套 用後: 0.5 列, 行距: 固定行高 23 pt, 貼齊格線
Inhibition of Hepatitis C Virus by Chinese Herbal Extracts---by the Mode of Cytokines secretion and Virus RNA
Transcription
Shang-Pang Huang
Major Professor：Jung-Chou Chen
Graduate Institute of Chinese Medical Science
China Medical University
Chronic hepatitis C has a high prevalent rate in Taiwan. Current IFN-based therapy fails to eradicate virus from all the infected individuals, and is least effective for those who harbor genotype 1b Hepatitis C Virus (HCV), which is the predominant type found in Taiwan. Thus there is urgent need to improve anti-HCV therapies and discover novel therapeutic approaches in the form of new antiviral agents. Previous studies on Interferon (IFN)-ribavirin combined treatment and some herbal medicines such as Xiao Chai Hu Tang have linked their antiviral effects to immune modulation. In this study, we would like to demonstrate that Xiao Chai Hu Tang modulates host immune responses through the alteration of cytokine production profiles. Our preliminary results have demonstrated that the cytokine productions in Human Peripheral Blood Mononeucloid Cells (PBMCs) could be selectively regulated by Xiao Chai Hu Tang. By turning off the inflammation responses and in the same time promoting T-helper cells-1(Th-1) responses, Xiao Chai Hu Tang may help to alleviate symptoms of hepatitis. Some patients are resistant to IFN-α treatment, thus improving anti-HCV therapies and discovering novel therapeutic approaches in the form of new antiviral agents have acquired great urgency. However Xiao Chai Hu Tang did not show any repression effects on HCV replication ability. Recently, human hepatoma-derived Huh7 cell lines supporting
格式化: 縮排: 第一行: 10.5
replication of an engineered copy of subgenomic HCV RNA, in place of the viral structural genes, have been established.Using RT-PCR, real-time PCR and the MTS assay, we examined the suppression of HCV replication and the cytotoxicity of 11 aqueous extracts and 8 compounds using Chinese herbs traditionally used for liver protection. Desmodium caudatum (Thunb.),
Canna indica L. (Cannaceae), and two commercial extracts from Ganoderma tsugua, Triterpenoids Enterprise (Shuang Hor Lingzhi
R) and Polysaccharides Enterprise (Shuang Hor Supreme LingzhiR), substantially inhibited HCV replication at 1 mg/ml in Huh7 human hepatoma cells containing an HCV subgenomic replicon. In addition, HCV-Huh7 cells treated with a combination of a low dose (10 IU/ml) of IFN- and 1 mg/ml of one of the four herbal extracts also exhibited significant inhibition of HCV replication. Thus, D. caudatum , C. indica, Triterpenoids Enterprise and Polysaccharides Enterprise are possible sources of potent anti-HCV agents.Key words: Hepatitis C virus; Xiao Chai Hu Tang; hepatitis C virus;
peripheral blood mononuclear cells; cytokines; anti-HCV agents;
Triterpenoids Enterprise; Polysaccharides Enterprise; Desmodium caudatum;
Canna indica
family for each Latin binomial
is required at first mention in
abstract and in text.
刪除: (these)
刪除: (Shuang Hor LingzhiR), 刪除: (Shuang Hor Supreme LingzhiR)
謝辭
自從我民國 88 年有幸考取中醫研究所博士班以來，求學與研究的 過程實可謂從千辛萬苦中一路披荊斬棘乃至於今；期間千祐與譯民的來 臨，上祐中醫診所成立，因為指導教授離開學校，以致休學三年，接腫 而至的是診所新建大樓施工與落成，因洪喬之誤導致博士論文投稿遭退 件，及至去年底因學校董事會為爭取全球五百大而決議修改畢業資格幾 乎使得我博士班的努力功敗垂成………….
但是，這接連而來的逆境因為有我指導教授陳榮洲老師一路的支 持，使得我能夠堅定爭取畢業的決心不至動搖，同時我更要感謝林昭庚 教授在最後關頭給了我最重要的協助，內人甚至感慨的說林老師是我生 命中的貴人。真的，自從我進了中國醫藥大學以來一直都是；鐘景光老 師是我一直無緣追隨學習卻也給了我無以言謝的幫助，離校在即，自忖 拙作終歸是學海之一粟，三日之後當乏人問津，然而諸多師恩浩蕩卻是 在我風馳電掣的人生旅途中不敢須臾忘懷的，爰引數辭，藉以聊表永誌 之心!
黃上邦
2008/07/31 謹識於斗六